Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 1 | 1 |
Echinococcus multilocularis | lamin dm0 | 0.0026 | 1 | 1 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.7405 | 0.5 |
Echinococcus multilocularis | musashi | 0.0026 | 1 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.7405 | 0.7405 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.7405 | 0.5 |
Trypanosoma brucei | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.7405 | 0.5 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.7405 | 0.7405 |
Schistosoma mansoni | lamin | 0.0026 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease | 0.0023 | 0.7405 | 0.5 |
Brugia malayi | exodeoxyribonuclease III family protein | 0.0023 | 0.7405 | 0.7108 |
Leishmania major | apurinic/apyrimidinic endonuclease-redox protein | 0.0023 | 0.7405 | 0.5 |
Echinococcus multilocularis | lamin | 0.0026 | 1 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.7405 | 0.5 |
Plasmodium falciparum | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.7405 | 0.5 |
Echinococcus granulosus | intermediate filament protein | 0.0026 | 1 | 1 |
Trypanosoma cruzi | apurinic/apyrimidinic endonuclease, putative | 0.0023 | 0.7405 | 0.5 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.7405 | 0.5 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.7405 | 0.5 |
Schistosoma mansoni | intermediate filament proteins | 0.0026 | 1 | 1 |
Brugia malayi | Cytochrome P450 family protein | 0.0022 | 0.6884 | 0.6527 |
Toxoplasma gondii | exonuclease III APE | 0.0023 | 0.7405 | 0.5 |
Echinococcus granulosus | lamin dm0 | 0.0026 | 1 | 1 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.7405 | 0.5 |
Echinococcus granulosus | lamin | 0.0026 | 1 | 1 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.7405 | 0.7405 |
Schistosoma mansoni | lamin | 0.0026 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0026 | 0.9646 | 0.9646 |
Onchocerca volvulus | 0.0026 | 1 | 0.5 | |
Brugia malayi | Intermediate filament tail domain containing protein | 0.0026 | 1 | 1 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.7405 | 0.5 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.7405 | 0.5 |
Onchocerca volvulus | 0.0026 | 1 | 0.5 | |
Plasmodium vivax | AP endonuclease (DNA-[apurinic or apyrimidinic site] lyase), putative | 0.0023 | 0.7405 | 0.5 |
Loa Loa (eye worm) | intermediate filament tail domain-containing protein | 0.0026 | 1 | 1 |
Loa Loa (eye worm) | cytochrome P450 family protein | 0.0022 | 0.6884 | 0.6884 |
Loa Loa (eye worm) | cytoplasmic intermediate filament protein | 0.0014 | 0.1026 | 0.1026 |
Loa Loa (eye worm) | intermediate filament protein | 0.0026 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0024 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 28.1838 uM | PubChem BioAssay. qHTS for Agonist of gsp, the Etiologic Mutation Responsible for Fibrous Dysplasia/McCune-Albright Syndrome: qHTS. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504404] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.